These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31943645)

  • 21. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
    Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
    Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
    Odawara M; Miyagawa J; Iwamoto N; Takita Y; Imaoka T; Takamura T
    Diabetes Obes Metab; 2016 Mar; 18(3):249-57. PubMed ID: 26661514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
    Ferdinand KC; White WB; Calhoun DA; Lonn EM; Sager PT; Brunelle R; Jiang HH; Threlkeld RJ; Robertson KE; Geiger MJ
    Hypertension; 2014 Oct; 64(4):731-7. PubMed ID: 24980665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
    Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
    Takase T; Nakamura A; Yamamoto C; Nomoto H; Miya A; Dannoura M; Cho KY; Kurihara Y; Manda N; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2019 May; 10(3):699-705. PubMed ID: 30076787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved Clinical Outcomes with Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs with or Without Insulin in Overweight Indian Patients with Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting.
    Ghosh A; Nair R
    Curr Diabetes Rev; 2020; 16(5):490-496. PubMed ID: 31686642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GLP-1 Agonists in Type 1 Diabetes Mellitus.
    Janzen KM; Steuber TD; Nisly SA
    Ann Pharmacother; 2016 Aug; 50(8):656-65. PubMed ID: 27252246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 30. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
    Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
    Metabolism; 2020 May; 106():154190. PubMed ID: 32109448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
    Giorgino F; Guerci B; Füchtenbusch M; Lebrec J; Boye K; Orsini Federici M; Heitmann E; Dib A; Yu M; Sapin H; García-Pérez LE
    Diabetes Obes Metab; 2023 Dec; 25(12):3465-3477. PubMed ID: 37700627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
    Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
    Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Rev Clin Pharmacol; 2016; 9(3):385-99. PubMed ID: 26761217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
    Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
    Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide.
    An IB; Byun MS; Yang SI; Choi Y; Woo JW; Jang HC; Sung YC
    Diabetes Obes Metab; 2020 Aug; 22(8):1455-1468. PubMed ID: 32314505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
    Onishi Y; Oura T; Matsui A; Matsuura J; Iwamoto N
    Endocr J; 2017 May; 64(5):553-560. PubMed ID: 28367916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dulaglutide for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.